ARL Bio Pharma Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • ARL Bio Pharma's estimated annual revenue is currently $42.8M per year.(i)
  • ARL Bio Pharma's estimated revenue per employee is $201,000

Employee Data

  • ARL Bio Pharma has 213 Employees.(i)
  • ARL Bio Pharma grew their employee count by 20% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6M3058%N/AN/A
#2
$42.8M21320%N/AN/A
#3
$5.8M29-6%N/AN/A
#4
$2.6M138%N/AN/A
#5
$44.8M2235%N/AN/A
#6
$10.7M534%N/AN/A
#7
$5.6M280%N/AN/A
#8
$5.6M28-18%N/AN/A
#9
$9.2M46-8%N/AN/A
Add Company

What Is ARL Bio Pharma?

Contract Testing Laboratory ARL Bio Pharma provides analytical and microbiological testing for the pharmaceutical industry. ARL has been serving the clinical and pharmaceutical markets since 1998. ARL is well equipped with instrumentation, such as High Performance Liquid Chromatography (HPLC), HPLC-Tandem Mass spectrometry (HPLC/MS/MS), Gas Chromatography (GC), GC/MS, high resolution Fourier Transform Infrared (FT-IR), Polarimeter, ELISA, and Environmental Chambers. Our dedicated team of scientists and experts continually deliver research and scientific solutions for the compounding and pharmaceutical industries. ARL’s competent personnel with regulatory expertise provide a comprehensive approach to analytical and microbiology testing, forensic analysis, and pharmaceutical testing. ARL is an FDA registered analytical laboratory and DEA licensed. ARL is ISO 17025:2005 accredited as applicable to our scope of accreditation. ISO outlines general requirements for the competence of testing and calibration laboratories. An independent QA/QC department conducts internal audits of the laboratories as a part of our quality management system.

keywords:N/A

N/A

Total Funding

213

Number of Employees

$42.8M

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$59.1M2146%N/A
#2
N/A2156%N/A
#3
$64.7M2182%N/A
#4
$34M2180%$3.3M
#5
$7.5M22210%N/A